Romiplostim Not Tied to Leukemic Progression in Myelodysplastic Syndromes Romiplostim Not Tied to Leukemic Progression in Myelodysplastic Syndromes
Contrary to initial reports, romiplostim treatment of thrombocytopenia does not appear to increase the risk of progression from myelodysplastic syndrome (MDS) to acute myeloid leukemia (AML).Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 2, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Therapeutic Vaccine Combination May Help Patients with Myelodysplastic Syndrome
A new study demonstrates that it is possible to vaccinate patients with MDS against a decitabine-induced antigen and that the level of induced expression is sufficient to trigger cytotoxicity in patient-derived vaccine induced T-cells. (Source: CancerNetwork)
Source: CancerNetwork - January 30, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Hematologic Malignancies Myelodysplastic Syndromes News Source Type: news
Dana-Farber/Brigham and Women's physician wins prestigious recognition from ASH
(Dana-Farber Cancer Institute) Benjamin Ebert, M.D., Ph.D., current chair of Medical Oncology, was presented with recognition at annual American Society of Hematology meeting. Ebert is notable for his leadership in describing the genomic landscape of adult myelodysplastic syndromes (MDS). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 12, 2017 Category: Cancer & Oncology Source Type: news
Forty Seven Inc. Receives $5 Million Grant from The California Institute for Regenerative Medicine (CIRM) to Support Ongoing Clinical Trial in Acute Myeloid Leukemia
CIRM grant will support further development of Forty Seven Inc.'s CD47 antibody Hu5F9-G4 in an ongoing second trial for the treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome
MENLO PARK, Calif., Dec. 6, 2017 -- (Healthcare Sales & Marketin... Biopharmaceuticals, Regenerative Medicine, Oncology Forty Seven, acute myeloid leukemia, Myelodysplastic Syndrome, stem cell (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 6, 2017 Category: Pharmaceuticals Source Type: news
Five - Year Relative Survival 59.6 Percent in Lower - Risk Myelodysplastic Syndromes
Five - year overall survival 47.3 percent in patients with lower - risk myelodysplastic syndromes (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 12, 2017 Category: Cancer & Oncology Tags: Oncology, Journal, Source Type: news
European Commission grants orphan drug status to Apogenix ’s asunercept for MDS
German biopharmaceutical company Apogenix ’s asunercept (APG101) has received orphan drug designation from the European Commission (EC) to treat patients with myelodysplastic syndromes (MDS). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 8, 2017 Category: Pharmaceuticals Source Type: news
Luspatercept Eyes Treatment of Anemia in Low-Risk MDS Luspatercept Eyes Treatment of Anemia in Low-Risk MDS
Luspatercept, an investigational agent, shows promise in treating anemia in low-risk myelodysplastic syndromes based on a phase 2 study. Larger studies are underway.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 27, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Medical News Today: MDS symptoms: What are the signs of pre-leukemia?
MDS, or myelodysplastic syndrome, refers to a group of blood cancers. In this article, learn about the symptoms and complications of this disease. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 15, 2017 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news
Gamida Cell launches severe aplastic anemia trial
Gamida Cell said today that the first patient has been transplanted in a study of its CordIn product for patients with severe aplastic anemia or hypoplastic myelodysplastic syndrome.
The product is designed for patients with rare genetic diseases who have no fully-matched donors for a bone marrow transplantation. Gamida Cell said it is also evaluating its CordIn therapy for patients with sickle cell disease.
Get the full story at our sister site, Drug Delivery Business News.
The post Gamida Cell launches severe aplastic anemia trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 21, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Research & Development Stem Cells Gamida Cell Source Type: news
Gamida Cell Announces First Patient Transplanted in Phase 1/2 Study of CordIn for Severe Aplastic Anemia and Hypoplastic MDS
This investigator initiated study is being conducted in collaboration with the U.S. National Heart, Lung and Blood Institute (NHLBI)
JERUSALEM, Aug. 21, 2017 -- (Healthcare Sales & Marketing Network) -- The first subject has been transplanted in an in... Biopharmaceuticals Gamida Cell, Cordin, aplastic anemia, myelodysplastic syndrome (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 21, 2017 Category: Pharmaceuticals Source Type: news
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
This research article has led to a Practice Changing Update on DynaMed Plus. It found that myeloablative conditioning increases relapse-free survival, but also increases treatment-related mortality compared to reduced intensity conditioning in patients with acute myeloid leukemia or myelodysplastic syndromes having first allogeneic hematopoietic cell transplantation (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 30, 2017 Category: Consumer Health News Source Type: news
FDA allows marketing of test to aid in the detection of certain leukemias and lymphomas
The U.S. Food and Drug Administration today allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorized test for use with flow cytometry to aid in the detection of several leukemias and lymphomas, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). (Source: Food and Drug Administration)
Source: Food and Drug Administration - June 29, 2017 Category: American Health Source Type: news
Helsinn and MEI begin dosing in Phase II combination trial to treat MDS
Swiss pharmaceutical group Helsinn and US-based oncology firm MEI Pharma have begun dosing patients in a Phase II clinical trial of pracinostat and azacitidine combination for the treatment of patients with myelodysplastic syndromes (MDS). (Source: Drug Development Technology)
Source: Drug Development Technology - June 15, 2017 Category: Pharmaceuticals Source Type: news
Survival in MDS Equivalent With Reduced-Intensity Conditioning
Patients with myelodysplastic syndrome undergoing a reduced –intensity conditioning regimen prior to allogeneic stem-cell transplantation had similar 2-year survival outcomes as patients who underwent myeloablative conditioning. (Source: CancerNetwork)
Source: CancerNetwork - May 9, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Myelodysplastic Syndromes News Source Type: news
Results of prospective randomized phase III study of the EBMT (Ricmac trial) dose-reduced versus standard conditioning followed by allogeneic stem cell transplantation for patients with myelodysplastic syndrome
(European Society for Blood and Marrow Transplantation) The EBMT announces the results from the RICMAC trial, published in the Journal of Clinical Oncology on Tuesday 2 May 2017. These results show evidence that reduced-intensity conditioning regimen (RIC) result in at least a 2-year relapse-free survival and overall survival similar to standard conditioning regimen (MAC) in patients with MDS or secondary acute AML. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 4, 2017 Category: Global & Universal Source Type: news
